ThinkSabio

$NTLA

$12.59▲ -0.1% YTD

10 SEC 13D/G filings tracked · Last updated Oct 13, 2026

Filing History
News
NTLA ▼ -0.1% - Intellia Therapeutics, Inc.
CP $12.59▲ -0.1%Oct 13, 2026 · ThinkSabio Blog

$NTLA - Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer…

News
NTLA ▼ -4.8% - Intellia Therapeutics, Inc.
CP $11.78▲ -4.8%Oct 7, 2026 · ThinkSabio Blog

$NTLA down into close…

News
NTLA ▼ -2.4% - Intellia Therapeutics, Inc.
CP $12.45▲ -2.4%Oct 6, 2026 · ThinkSabio Blog

$NTLA int Underweight @ Barclays pt 8…

News
NTLA ▲ +0.6% - Intellia Therapeutics, Inc.
CP $12.26▲ +0.6%Oct 2, 2026 · ThinkSabio Blog

$NTLA - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)…

News
NTLA ▲ +0.9% - Intellia Therapeutics, Inc.
CP $12.16▲ +0.9%Oct 2, 2026 · ThinkSabio Blog

$NTLA Cathie Wood's ARK Investment buys 411K shares of Intellia Therapeutics today…

News
NTLA ▲ +0.7% - Intellia Therapeutics, Inc.
CP $12.30▲ +0.7%Sep 10, 2026 · ThinkSabio Blog

$NTLA Cathie Wood's ARK Investment buys 204K shares of Intellia Therapeutics…

News
NTLA ▲ +5.7% - Intellia Therapeutics, Inc.
CP $13.46▲ +5.7%Sep 8, 2026 · ThinkSabio Blog

$NTLA - Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for H…

News
NTLA ▲ +0.2% - Intellia Therapeutics, Inc.
CP $12.70▲ +0.2%Sep 4, 2026 · ThinkSabio Blog

$NTLA - Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million…

News
NTLA ▲ +1.1% - Intellia Therapeutics, Inc.
CP $12.79▲ +1.1%Sep 3, 2026 · ThinkSabio Blog

$NTLA Cathie Wood's ARK Investment buys 96.2K shares of Intellia Therapeutics today…

SEC 13D/G
NTLA - Intellia Therapeutics, Inc. - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks Simplified
$11.57▲ 25.35%Aug 7, 2026 · ThinkSabio Blog

$NTLA SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #NTLA Intellia Therapeutics, Inc. : $11.57 Sector: Healthcare |…